Alan D. Michelson

Publications

1. Platelet Pathophysiology: Unexpected New Research Directions. Semin Thromb Hemost. 2024 Nov; 50(8):1187-1190. View Abstract
2. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 05 15; 14(1):11092. View Abstract
3. Platelet Physiology. Semin Thromb Hemost. 2024 Nov; 50(8):1173-1186. View Abstract
4. Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. Blood. 2022 09 29; 140(13):1470-1481. View Abstract
5. Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. J Clin Pharmacol. 2022 02; 62(2):220-231. View Abstract
6. Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia. Immunity. 2022 02 08; 55(2):224-236.e5. View Abstract
7. Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. Clin Ther. 2021 12; 43(12):2074-2087. View Abstract
8. Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. Atherosclerosis. 2021 12; 339:12-19. View Abstract
9. Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease. Thromb Haemost. 2022 06; 122(6):951-960. View Abstract
10. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. J Thromb Haemost. 2021 12; 19(12):3193-3202. View Abstract
11. Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. J Am Heart Assoc. 2021 11 16; 10(22):e021765. View Abstract
12. Familial thrombocytopenia due to a complex structural variant resulting in a WAC-ANKRD26 fusion transcript. J Exp Med. 2021 06 07; 218(6). View Abstract
13. Immunophenotypic Analysis of Platelets by Flow Cytometry. Curr Protoc. 2021 Jun; 1(6):e178. View Abstract
14. Platelet Immunophenotyping by High-Dimensional Mass Cytometry. Curr Protoc. 2021 May; 1(5):e112. View Abstract
15. Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. PLoS One. 2021; 16(4):e0249209. View Abstract
16. Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. Blood. 2021 04 15; 137(15):2010-2020. View Abstract
17. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681. View Abstract
18. Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. J Thromb Haemost. 2021 04; 19(4):976-982. View Abstract
19. Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters. Cytometry A. 2021 02; 99(2):170-179. View Abstract
20. Platelet surface GPIba, activated GPIIb-IIIa, and P-selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. Platelets. 2022 Jan 02; 33(1):116-122. View Abstract
21. Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood. 2020 10 22; 136(17):1956-1967. View Abstract
22. Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Res Pract Thromb Haemost. 2020 Jul; 4(5):680-713. View Abstract
23. Novel Antiplatelet Agents in Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2020 05; 25(3):191-200. View Abstract
24. An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension. Diabetologia. 2020 04; 63(4):733-743. View Abstract
25. Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. Br J Haematol. 2020 03; 188(6):945-961. View Abstract
26. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemp Clin Trials. 2019 10; 85:105835. View Abstract
27. Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the UNIVERSE study). Am Heart J. 2019 07; 213:97-104. View Abstract
28. Usefulness of anti-platelet therapy testing in children supported with a ventricular assist device. J Heart Lung Transplant. 2019 07; 38(7):781-783. View Abstract
29. Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Med Hypotheses. 2019 Apr; 125:100-105. View Abstract
30. PF-04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placebo-Controlled Study. Clin Transl Sci. 2019 03; 12(2):180-188. View Abstract
31. Publisher Correction: GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 Nov 29; 8(1):17580. View Abstract
32. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018 12; 16(12):2515-2519. View Abstract
33. GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Sci Rep. 2018 09 28; 8(1):14529. View Abstract
34. Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS One. 2018; 13(9):e0203557. View Abstract
35. Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. Sci Rep. 2018 07 09; 8(1):10300. View Abstract
36. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost. 2018 Jul; 2(3):439-449. View Abstract
37. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. J Thromb Haemost. 2018 03; 16(3):607-608. View Abstract
38. Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thromb Haemost. 2018 01; 118(1):143-151. View Abstract
39. Immature platelet fraction in immune thrombocytopenia: Useful in diagnosis but does it predict bleeding? Pediatr Blood Cancer. 2018 02; 65(2). View Abstract
40. High serum serotonin in sudden infant death syndrome. Proc Natl Acad Sci U S A. 2017 07 18; 114(29):7695-7700. View Abstract
41. How I use laboratory monitoring of antiplatelet therapy. Blood. 2017 08 10; 130(6):713-721. View Abstract
42. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. J Thromb Haemost. 2017 05; 15(5):858-867. View Abstract
43. Whole Blood Analysis of Leukocyte-Platelet Aggregates. Curr Protoc Cytom. 2016 10 10; 78:6.15.1-6.15.10. View Abstract
44. Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. PLoS One. 2016; 11(8):e0160933. View Abstract
45. Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. Biomed Microdevices. 2016 08; 18(4):73. View Abstract
46. Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thromb Haemost. 2016 07 04; 116(1):69-77. View Abstract
47. Platelet Physiology. Semin Thromb Hemost. 2016 Apr; 42(3):191-204. View Abstract
48. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. Arterioscler Thromb Vasc Biol. 2016 Mar; 36(3):501-9. View Abstract
49. In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. Platelets. 2016 Jun; 27(4):308-16. View Abstract
50. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. Eur J Med Chem. 2016 Jan 01; 107:204-18. View Abstract
51. Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. Platelets. 2016; 27(3):196-202. View Abstract
52. Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. PLoS One. 2015; 10(8):e0134599. View Abstract
53. Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. Blood. 2015 Sep 10; 126(11):1367-78. View Abstract
54. Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood. 2015 Aug 13; 126(7):873-9. View Abstract
55. Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. Platelets. 2016; 27(2):128-35. View Abstract
56. Platelet geometry sensing spatially regulates a-granule secretion to enable matrix self-deposition. Blood. 2015 Jul 23; 126(4):531-8. View Abstract
57. Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on thrombosis in pediatric cardiology and congenital heart disease. Circulation. 2014 Sep 30; 130(14):1192-203. View Abstract
58. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. J Trauma Acute Care Surg. 2014 Sep; 77(3 Suppl 2):S94-S100. View Abstract
59. Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trial. J Am Coll Cardiol. 2014 Jul 29; 64(4):361-8. View Abstract
60. Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? Int J Lab Hematol. 2015 Feb; 37(1):112-9. View Abstract
61. Antiplatelet activity, P2Y1 and P2Y12 inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'?-P¹ ,P4-dithio-P²,P³-chloromethylenetetraphosphate. PLoS One. 2014; 9(4):e94780. View Abstract
62. Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. BMJ Open. 2014 Jan 17; 4(1):e003883. View Abstract
63. Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. J Thromb Haemost. 2014 Jan; 12(1):2-13. View Abstract
64. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Acta Haematol. 2013; 130(3):181-7. View Abstract
65. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. Blood. 2013 Jul 18; 122(3):376-85. View Abstract
66. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. J Am Heart Assoc. 2013 May 15; 2(3):e000026. View Abstract
67. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. J Thromb Haemost. 2013 May; 11(5):1002-3. View Abstract
68. Recommendations for the Standardization of Light Transmission Aggregometry: A Consensus of the Working Party from the Platelet Physiology Subcommittee of SSC/ISTH. J Thromb Haemost. 2013 Apr 10. View Abstract
69. Platelet activation and inhibition in sickle cell disease (pains) study. Platelets. 2014; 25(1):27-35. View Abstract
70. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013 Feb 26; 61(8):872-9. View Abstract
71. Gray platelet syndrome. Blood. 2013 Jan 10; 121(2):250. View Abstract
72. Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. J Thromb Haemost. 2012 Dec; 10(12):2573-80. View Abstract
73. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012 Sep 25; 126(13):1645-62. View Abstract
74. Granule exocytosis is required for platelet spreading: differential sorting of a-granules expressing VAMP-7. Blood. 2012 Jul 05; 120(1):199-206. View Abstract
75. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012 Apr 03; 59(14):1304-11. View Abstract
76. Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. Platelets. 2012; 23(6):430-8. View Abstract
77. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26; 119(17):4066-72. View Abstract
78. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8. View Abstract
79. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. J Thromb Haemost. 2011 Nov; 9(11):2302-10. View Abstract
80. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. PLoS One. 2011; 6(9):e24549. View Abstract
81. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44. Thromb Haemost. 2011 Aug; 106(2):219-26. View Abstract
82. Effects of in vitro adult platelet transfusions on neonatal hemostasis. J Thromb Haemost. 2011 May; 9(5):1020-8. View Abstract
83. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. J Clin Sleep Med. 2011 Apr 15; 7(2):172-8. View Abstract
84. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J. 2011 Apr; 32(7):838-46. View Abstract
85. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics. 2011 Feb; 127(2):347-57. View Abstract
86. Advances in antiplatelet therapy. Hematology Am Soc Hematol Educ Program. 2011; 2011:62-9. View Abstract
87. The Platelet Activity After Clopidogrel Termination (PACT) study. Circ Cardiovasc Interv. 2010 Oct; 3(5):442-9. View Abstract
88. Thrombophilia and pediatric stroke. Circulation. 2010 Apr 27; 121(16):1795-7. View Abstract
89. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov. 2010 Feb; 9(2):154-69. View Abstract
90. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets. 2010; 21(7):525-32. View Abstract
91. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009 Dec 22; 120(25):2586-96. View Abstract
92. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res. 2010 Feb; 125(2):159-65. View Abstract
93. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost. 2010 Feb; 8(2):331-40. View Abstract
94. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets. 2009 Nov; 20(7):513-9. View Abstract
95. New P2Y12 antagonists. Curr Opin Hematol. 2009 Sep; 16(5):371-7. View Abstract
96. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009 Sep 19; 374(9694):989-997. View Abstract
97. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J. 2009 Jul; 30(14):1753-63. View Abstract
98. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. J Thromb Haemost. 2009 Jun; 7(6):1029. View Abstract
99. Methods for the measurement of platelet function. Am J Cardiol. 2009 Feb 02; 103(3 Suppl):20A-26A. View Abstract
100. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. Thromb Res. 2009 May; 124(1):42-5. View Abstract
101. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J Thromb Haemost. 2008 Dec; 6(12):2035-44. View Abstract
102. Platelet antistaphylococcal responses occur through P2X1 and P2Y12 receptor-induced activation and kinocidin release. Infect Immun. 2008 Dec; 76(12):5706-13. View Abstract
103. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. J Thromb Thrombolysis. 2009 Jul; 28(1):31-7. View Abstract
104. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):887S-968S. View Abstract
105. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):345-52. View Abstract
106. Antiplatelet therapy and platelet function testing. Introduction. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I1. View Abstract
107. Assessing the current role of platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I10-6. View Abstract
108. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I17-20. View Abstract
109. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I2-9. View Abstract
110. Investigating the mechanisms of hyporesponse to antiplatelet approaches. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I21-7. View Abstract
111. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I28-35. View Abstract
112. Antiplatelet therapy and platelet function testing. Clin Cardiol. 2008 Mar; 31(3 Suppl 1):I36. View Abstract
113. Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. Circulation. 2008 Jan 29; 117(4):553-9. View Abstract
114. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):s33-8. View Abstract
115. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007 Dec 18; 116(25):2923-32. View Abstract
116. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008 02; 6(2):359-65. View Abstract
117. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007 Nov 06; 50(19):1822-34. View Abstract
118. Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models. Thromb Res. 2008; 121(5):689-98. View Abstract
119. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007 Jul; 98(1):192-200. View Abstract
120. Cystic fibrosis heterozygotes do not have increased platelet activation. Thromb Res. 2007; 121(2):159-62. View Abstract
121. Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007 Apr; 5(4):761-5. View Abstract
122. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007; 120(3):323-36. View Abstract
123. Arterial ischemic stroke in children: baby steps. Circulation. 2006 Nov 14; 114(20):2094-5. View Abstract
124. Current options in platelet function testing. Am J Cardiol. 2006 Nov 20; 98(10A):4N-10N. View Abstract
125. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost. 2007 Jan; 5(1):75-81. View Abstract
126. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. J Thromb Haemost. 2006 Dec; 4(12):2670-7. View Abstract
127. Frequency of aspirin resistance in a community hospital. Am J Cardiol. 2006 Sep 01; 98(5):577-9. View Abstract
128. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006 Jun 27; 113(25):2888-96. View Abstract
129. Aspirin resistance. Pathophysiol Haemost Thromb. 2006; 35(1-2):5-9. View Abstract
130. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb. 2006; 35(1-2):67-82. View Abstract
131. Platelet activation and progression to complications. Rev Cardiovasc Med. 2006; 7(2):75-81. View Abstract
132. Therapeutic goals for effective platelet inhibition: a consensus document. Rev Cardiovasc Med. 2006; 7(4):214-25. View Abstract
133. The inflammatory role of platelets in cystic fibrosis. Am J Respir Crit Care Med. 2006 Mar 01; 173(5):483-90. View Abstract
134. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005 Nov; 3(11):2563-70. View Abstract
135. Noncompliance in cardiovascular clinical trials. Am Heart J. 2005 Nov; 150(5):882-6. View Abstract
136. Clopidogrel linking evaluation of platelet response variability to mechanism of action. J Am Coll Cardiol. 2005 Aug 16; 46(4):646-7. View Abstract
137. Aspirin resistance and its implications in clinical practice. MedGenMed. 2005 Jul 11; 7(3):76. View Abstract
138. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005 Jun; 3(6):1309-11. View Abstract
139. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635-41. View Abstract
140. Survival of baboon biotin-X-N-hydroxysuccinimide and (111)In-oxine-labelled autologous fresh and lyophilized reconstituted platelets. Vox Sang. 2005 Feb; 88(2):122-9. View Abstract
141. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemost. 2005 Feb; 3(2):312-20. View Abstract
142. Antiplatelet therapy in children. Thromb Res. 2006; 118(1):75-83. View Abstract
143. Platelet function testing in cardiovascular diseases. Hematology. 2005; 10 Suppl 1:132-7. View Abstract
144. Platelet function testing in cardiovascular diseases. Circulation. 2004 Nov 09; 110(19):e489-93. View Abstract
145. In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. Transfusion. 2004 Oct; 44(10):1505-12. View Abstract
146. Application of flow cytometry to platelet disorders. Semin Thromb Hemost. 2004 Oct; 30(5):501-11. View Abstract
147. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):645S-687S. View Abstract
148. GPIIb/IIIa inhibitor-induced dethrombosis. J Thromb Thrombolysis. 2004 Aug; 18(1):11-7. View Abstract
149. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004 Jun 16; 43(12):2319-25. View Abstract
150. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. Am J Cardiol. 2003 Nov 01; 92(9):1099-101. View Abstract
151. How platelets work: platelet function and dysfunction. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):7-12. View Abstract
152. Platelet inhibitor therapy: mechanisms of action and clinical use. J Thromb Thrombolysis. 2003 Aug-Oct; 16(1-2):13-5. View Abstract
153. Neonatal platelet function. Semin Thromb Hemost. 2003 Aug; 29(4):363-72. View Abstract
154. Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. Blood. 2003 Oct 15; 102(8):2843-50. View Abstract
155. Whole blood analysis of leukocyte-platelet aggregates. Curr Protoc Cytom. 2003 May; Chapter 6:Unit 6.15. View Abstract
156. Platelet FcgammaRIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. J Thromb Haemost. 2003 Feb; 1(2):355-62. View Abstract
157. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. J Vasc Surg. 2003 Feb; 37(2):440-5. View Abstract
158. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J. 2003 Feb; 145(2):e6. View Abstract
159. Two novel mutations in the alpha IIb calcium-binding domains identify hydrophobic regions essential for alpha IIbbeta 3 biogenesis. Blood. 2003 Mar 15; 101(6):2268-76. View Abstract
160. Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. Cardiovasc Surg. 2002 Oct; 10(5):464-9. View Abstract
161. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost. 2002 Jun; 87(6):1020-5. View Abstract
162. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 2002 Apr; 143(4):602-11. View Abstract
163. Immunophenotypic analysis of platelets. Curr Protoc Cytom. 2002 Feb; Chapter 6:Unit 6.10. View Abstract
164. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J. 2001 Nov; 142(5):790-8. View Abstract
165. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 2001 Oct; 38(4):1002-6. View Abstract
166. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation. 2001 Sep 25; 104(13):1533-7. View Abstract
167. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. Circulation. 2001 Sep 18; 104(12):1374-9. View Abstract
168. Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. Blood. 2001 Sep 01; 98(5):1440-7. View Abstract
169. Serial determinations of platelet counts in mice by flow cytometry. Thromb Haemost. 2001 Aug; 86(2):668-71. View Abstract
170. Laser scanning cytometry: a novel method for the detection of platelet--endothelial cell adhesion. Cytometry. 2001 Apr 01; 43(4):308-13. View Abstract
171. Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIbbeta3 activation. Mol Microbiol. 2001 Jan; 39(2):330-40. View Abstract
172. Antithrombotic therapy in children. Chest. 2001 Jan; 119(1 Suppl):344S-370S. View Abstract
173. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. Thromb Haemost. 2000 Nov; 84(5):897-903. View Abstract
174. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. Thromb Haemost. 2000 Oct; 84(4):689-94. View Abstract
175. Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents. Curr Cardiol Rep. 2000 Sep; 2(5):386-94. View Abstract
176. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. Thromb Haemost. 2000 Sep; 84(3):492-8. View Abstract
177. Evaluation of platelet function by flow cytometry. Methods. 2000 Jul; 21(3):259-70. View Abstract
178. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation. 2000 Mar 07; 101(9):1013-8. View Abstract
179. Nitric oxide insufficiency and arterial thrombosis. Trans Am Clin Climatol Assoc. 2000; 111:158-63. View Abstract
180. Flow cytometric analysis of platelets. Vox Sang. 2000; 78 Suppl 2:137-42. View Abstract
181. Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. Hematology Am Soc Hematol Educ Program. 2000; 222-240. View Abstract
182. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. J Vasc Surg. 1999 Nov; 30(5):844-51. View Abstract
183. Laboratory markers of platelet activation and their clinical significance. Curr Opin Hematol. 1999 Sep; 6(5):342-8. View Abstract
184. Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity. Transfusion. 1999 Aug; 39(8):880-8. View Abstract
185. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. Arterioscler Thromb Vasc Biol. 1999 Aug; 19(8):2017-23. View Abstract
186. Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble p-selectin during plateletpheresis. Transfusion. 1999 Jul; 39(7):735-41. View Abstract
187. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. J Biol Chem. 1999 May 14; 274(20):14368-75. View Abstract
188. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999 Jan; 117(1):172-83; discussion 183-4. View Abstract
189. The effects of aspirin and hypothermia on platelet function in vivo. Br J Haematol. 1999 Jan; 104(1):64-8. View Abstract
190. Antithrombotic therapy in children. Chest. 1998 Nov; 114(5 Suppl):748S-769S. View Abstract
191. Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. Am J Kidney Dis. 1998 Jul; 32(1):132-8. View Abstract
192. Patients with venous stasis ulceration have increased monocyte-platelet aggregation. J Vasc Surg. 1998 Jun; 27(6):1109-15; discussion 1115-6. View Abstract
193. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998 May; 79(5):885-96. View Abstract
194. Guidelines for antithrombotic therapy in pediatric patients. J Pediatr. 1998 Apr; 132(4):575-88. View Abstract
195. The cleaved peptide of the thrombin receptor is a strong platelet agonist. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3082-7. View Abstract
196. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. J Am Coll Cardiol. 1998 Feb; 31(2):352-8. View Abstract
197. Platelet function in the newborn. Semin Thromb Hemost. 1998; 24(6):507-12. View Abstract
198. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest. 1997 Jul 15; 100(2):350-6. View Abstract
199. Platelet hyporeactivity in very low birth weight neonates. Thromb Haemost. 1997 May; 77(5):1002-7. View Abstract
200. The prevention and treatment of thromboembolic disease in children: a need for Thrombophilia Programs. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):7-22. View Abstract
201. Flow cytometric assessment of glycoprotein movements in platelets. Platelets. 1997; 8(2-3):105-15. View Abstract
202. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11877-82. View Abstract
203. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg. 1996 Oct; 112(4):1098-107. View Abstract
204. Variability of platelet degranulation by different contrast media. Acad Radiol. 1996 Sep; 3 Suppl 3:S485-7. View Abstract
205. Effect of heparin on fibrinolytic activity and platelet function in vivo. Am J Physiol. 1996 Aug; 271(2 Pt 2):H528-34. View Abstract
206. Platelets are degranulated by some, but not all, contrast media. Acad Radiol. 1996 Aug; 3 Suppl 2:S328-30. View Abstract
207. Flow cytometry: a clinical test of platelet function. Blood. 1996 Jun 15; 87(12):4925-36. View Abstract
208. Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am J Physiol. 1996 May; 270(5 Pt 2):H1640-8. View Abstract
209. Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. J Surg Res. 1996 Mar; 61(2):543-8. View Abstract
210. The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. Blood. 1996 Feb 15; 87(4):1396-408. View Abstract
211. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest. 1996 Feb 15; 97(4):979-87. View Abstract
212. Images in clinical medicine. A morphologic question. N Engl J Med. 1995 Oct 19; 333(16):1051. View Abstract
213. Antithrombotic therapy in children. Chest. 1995 Oct; 108(4 Suppl):506S-522S. View Abstract
214. Fibrinolysis inhibits shear stress-induced platelet aggregation. Circulation. 1995 Sep 15; 92(6):1399-407. View Abstract
215. Platelet degranulation induced by some contrast media is independent of their nonionic vs ionic nature. Acta Radiol Suppl. 1995; 399:182-4. View Abstract
216. [Vestibular lesion in sudden deafness: a prognostic criterium for therapeutic success]. Laryngorhinootologie. 1995 Jan; 74(1):7-12. View Abstract
217. Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thromb Haemost. 1994 Dec; 72(6):957-63. View Abstract
218. Platelet activation results in a redistribution of glycoprotein IV (CD36). Arterioscler Thromb. 1994 Jul; 14(7):1193-201. View Abstract
219. Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood. 1994 Jul 01; 84(1):158-68. View Abstract
220. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood. 1994 Jun 15; 83(12):3562-73. View Abstract
221. Effects of contrast media on platelet activation using flowing whole blood aggregometry and flow cytometry of platelet membrane glycoproteins. Invest Radiol. 1994 Jun; 29 Suppl 2:S198-200. View Abstract
222. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 1994 May; 71(5):633-40. View Abstract
223. Human neutrophil cathepsin G is a potent platelet activator. J Vasc Surg. 1994 Feb; 19(2):306-18; discussion 318-9. View Abstract
224. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis. 1994 Feb; 5(1):121-31. View Abstract
225. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol. 1993 Nov; 85(3):533-41. View Abstract
226. Nonionic contrast media. Procoagulants or clotting innocents? Invest Radiol. 1993 Nov; 28 Suppl 5:S21-4. View Abstract
227. Effect of strenuous exercise on platelet activation state and reactivity. Circulation. 1993 Oct; 88(4 Pt 1):1502-11. View Abstract
228. High-dose heparin suppresses platelet alpha granule secretion. J Vasc Surg. 1992 Jun; 15(6):1000-8; discussion 1008-9. View Abstract
229. Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex. Semin Thromb Hemost. 1992 Jan; 18(1):18-27. View Abstract
230. Thrombocytopenia associated with environmental exposure to polyurethane. Am J Hematol. 1991 Oct; 38(2):145-6. View Abstract
231. Platelet glycogen synthase: further characterization and effect of insulin. Thromb Res. 1991 Aug 15; 63(4):427-32. View Abstract
232. Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood. 1991 Apr 15; 77(8):1740-8. View Abstract
233. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood. 1991 Feb 15; 77(4):770-9. View Abstract
234. Effect of in vivo infusion of recombinant tissue-type plasminogen activator on platelet glycoprotein Ib. Thromb Res. 1990 Dec 01; 60(5):421-4. View Abstract
235. Plasmin-induced redistribution of platelet glycoprotein Ib. Blood. 1990 Nov 15; 76(10):2005-10. View Abstract
236. [The effect of endonasal paranasal sinus surgery on lung function of patients with bronchial asthma]. Laryngorhinootologie. 1990 Oct; 69(10):521-6. View Abstract
237. Chemotherapy-induced painful acral erythema in childhood: Burgdorf's reaction. Am J Pediatr Hematol Oncol. 1989; 11(1):44-5. View Abstract
238. Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib. J Clin Invest. 1988 Jun; 81(6):1734-40. View Abstract
239. Flow cytometric detection of distinct subpopulations of platelets in individual patients. Prog Clin Biol Res. 1988; 283:131-6. View Abstract
240. Thrombin-induced changes in platelet membrane glycoproteins. Prog Clin Biol Res. 1988; 283:159-62. View Abstract
241. Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. Blood. 1987 Nov; 70(5):1673-8. View Abstract
242. Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. J Lab Clin Med. 1987 Sep; 110(3):346-54. View Abstract
243. Transient neurological disorder associated with transient erythroblastopenia of childhood. Am J Pediatr Hematol Oncol. 1987; 9(2):161-3. View Abstract
244. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood. 1986 Dec; 68(6):1280-4. View Abstract
245. Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood. 1986 Jan; 67(1):19-26. View Abstract
246. Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. Blood. 1985 Aug; 66(2):423-7. View Abstract
247. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. Blood. 1985 Jan; 65(1):32-40. View Abstract
248. Haemolytic anaemia associated with acquired toxoplasmosis. Aust Paediatr J. 1984 Nov; 20(4):333-5. View Abstract
249. Inheritance of Diamond-Blackfan anemia. Med J Aust. 1982 Oct 30; 2(9):409-10. View Abstract
Show All Publications Show Fewer Publications